NASDAQ:TVGNW Tevogen Bio (TVGNW) Stock Price, News & Analysis $0.06 0.00 (-0.89%) As of 07/10/2026 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Tevogen Bio Stock (NASDAQ:TVGNW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.03▼$0.0652-Week Range$0.03▼$0.08Volume18,944 shsAverage Volume131,438 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing. The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors. Tevogen Bio has advanced multiple candidate therapies into preclinical studies and early-phase clinical trials, evaluating safety, dosing strategies and preliminary efficacy across diverse patient populations. Originating from translational immunology research at the Sheba Medical Center in Israel, Tevogen Bio secured exclusive rights to novel TCR technologies and subsequently established operations in the United States. The company completed a corporate transaction to become publicly listed on the Nasdaq under the ticker TVGNW, positioning it to accelerate clinical development and expand manufacturing capabilities. Headquartered in the United States, Tevogen Bio collaborates with leading academic institutions and clinical centers worldwide to optimize its T cell engineering processes and trial designs. The company’s leadership team combines expertise in cell therapy development, translational research and regulatory affairs with a shared commitment to delivering scalable immunotherapies for patients in need.AI Generated. May Contain Errors. Read More Receive TVGNW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGNW Stock News HeadlinesTevogen Bio Holdings Inc. Outlines Strategic Growth and Advancements in AI-Driven Healthcare SolutionsAugust 11, 2025 | quiverquant.comQTevogen Bio Holdings Inc. Secures $1 Million Funding to Advance Tevogen.AI Drug Discovery InitiativeAugust 7, 2025 | quiverquant.comQThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)Tevogen Bio Holdings Inc. Secures $1 Million Grant to Advance AI-Driven Drug Discovery InitiativeAugust 1, 2025 | quiverquant.comQTevogen Bio Grants Restricted Stock to CEOJuly 10, 2025 | tipranks.comTevogen Bio Holdings Enters $50M Sales AgreementJuly 3, 2025 | tipranks.comSee More Headlines TVGNW Stock Analysis - Frequently Asked Questions How have TVGNW shares performed this year? Tevogen Bio's stock was trading at $0.0422 at the start of the year. Since then, TVGNW stock has increased by 32.5% and is now trading at $0.0559. How do I buy shares of Tevogen Bio? Shares of TVGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/11/2026Next Earnings (Estimated)8/13/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 6 days, TVGNW's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:TVGNW CIK1860871 Webtevogen.com Phone877-838-6436FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:TVGNW) was last updated on 7/12/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
